๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease.

โœ Scribed by P Reiderer; GP Reynolds

Book ID
117942317
Publisher
John Wiley and Sons
Year
1980
Tongue
English
Weight
268 KB
Volume
9
Category
Article
ISSN
0306-5251

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

MAO-B inhibitors for the treatment of Pa
MAO-B inhibitors for the treatment of Parkinson's disease
๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 88 KB

## INTRODUCTION BACKGROUND Early attempts to enhance dopaminergic neurotransmission through inhibition of one of dopamine's major metabolizing enzyme -monoamine oxidase (MAO) -were made soon after the discovery of the striatal dopaminergic deficit and the efficacy of L-dopa. 1 However, side-effect

Effects of tyramine administration in Pa
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline
โœ J. Antonelle deMarcaida; Steven R. Schwid; William B. White; Karen Blindauer; St ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 76 KB

## Abstract Rasagiline is a novel, potent, and selective MAOโ€B inhibitor shown to be effective for Parkinson's disease. Traditional nonselective MAO inhibitors have been associated with dietary tyramine interactions that can induce hypertensive reactions. To test safety, tyramine challenges (50โ€“75